Conivaptan: Promise of treatment in heart failure

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 13, 2009, Pages 2161-2169

  Hoque, Mohammad Z ^a   Arumugham, Pradeep ^a   Huda, Nazmul ^a   Verma, Nitin ^a   Afiniwala, Mitul ^a   Karia, Darshak H ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Conivaptan; Heart failure; Hyponatremia; Vasopressin antagonism

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; AMLODIPINE; ARGIPRESSIN; CLARITHROMYCIN; CONIVAPTAN; DIGOXIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LIXIVAPTAN; MIDAZOLAM; MOZAVAPTAN; RELCOVAPTAN; RITONAVIR; RWJ 676070; SATAVAPTAN; SIMVASTATIN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART FAILURE; HUMAN; HYPERVOLEMIA; HYPONATREMIA; INJECTION SITE REACTION; LOADING DRUG DOSE; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THIRST;

BENZAZEPINES; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN;

EID: 68949099390     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903173237     Document Type: Review

References (38)

1. American Heart Association. Heart disease and stroke statistics - 2009 update. Dallas, Texas: American Heart Association; 2009
2. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004;9(3):179-185
3. Vazquez R, Bayes-Genis A, Cygankiewicz I, et al. The MUSIC risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 2009;30(9):1088-1096
4. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290(19):2581-2587
5. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28(8):980-988 (Pubitemid 47343897)
6. Krumholz HM, Chen YT, Bradford WD, Cerese J. Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. Am J Manag Care 1999;5(6):715-723 (Pubitemid 29296026)
7. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341(8):577-585
8. Mann DL, Kent RL, Parsons B, Cooper GT. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85(2):790-804
9. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-1321 (Pubitemid 36384098)
10. Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341(10):709-717
11. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82(5):1724-1729
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) Investigators and Committees: a randomised trial. Lancet 1999;353(9146):9-13
13. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283(10):1295-1302 (Pubitemid 30129796)
14. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334(21):1349-1355
15. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-1675 (Pubitemid 33126822)
16. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362(9386):772-776 (Pubitemid 37093917)
17. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-1676
18. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-771 (Pubitemid 37093916)
19. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327(10):669-677
20. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-766 (Pubitemid 37093915)
21. Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000;21(23):1967-1978 (Pubitemid 30943695)
22. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362(9386):777-781 (Pubitemid 37093918)
23. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987;82(6):1213-1219
24. Goldsmith SR, Francis GS, Cowley AW Jr, et al. Hemodynamic effects of infused arginine vasopressin in congestive heart failure. J Am Coll Cardiol 1986;8(4):779-783 (Pubitemid 16023631)
25. Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 1994;267(6 Pt 2):H2245-54
26. Clair MJ, King MK, Goldberg AT, et al. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure. J Pharmacol Exp Ther 2000;293(3):852-860 (Pubitemid 30417851)
27. Burnier M, Fricker AF, Hayoz D, et al. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. Eur J Clin Pharmacol 1999;55(9):633-637
28. Zeltser D, Rosansky S, van Rensburg H, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27(5):447-457 (Pubitemid 47482001)
29. Wright WL, Asbury WH, Gilmore JL, Samuels OB. Conivaptan for hyponatremia in the neurocritical care unit. Neurocrit Care 2009;11(1):6-13
30. Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-21
31. Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104(20):2417-2423 (Pubitemid 33108374)
32. Goldsmith SR, Elkayam U, Haught WH, et al. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14(8):641-647
33. Russell SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 2003;145(1):179-186 (Pubitemid 36034515)
34. Gheorghiade M, Gattis WA, Barbagelata A, et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003;145(Suppl 2):S51-54 (Pubitemid 36207925)
35. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107(21):2690-2696 (Pubitemid 36667242)
36. Arai Y, Fujimori A, Sudoh K, Sasamata M. Vasopressin receptor antagonists: potential indications and clinical results. Curr Opin Pharmacol 2007;7(2):124-129 (Pubitemid 46404744)
37. Clinicaltrials.gov Registry: Diuretic and renal effects of vaprisol when administered along with furosemide and nesiritide continuous infusion http:// www.clinicaltrials.gov/ct2/show/ NCT00806910?term=conivaptan&rank=7
38. Clinicaltrials.gov Registry: Safety and efficacy of conivaptan in hyponatremic patients with symptomatic Acute Decompensated Heart Failure (ADHF) (CONVERT-H)http:// www.clinicaltrials.gov/ct2/show/ NCT00843986?term= conivaptan&rank=9